New therapeutic strategy for mood disorders

Current Medicinal Chemistry

Volumn 18, Issue 28, 2011, Pages 4284-4298

  Crupi, R ^a   Marino, A ^b   Cuzzocrea, S ^a,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Animal models; Antidepressants; Hippocampus; Mood disorders; Neurogenesis; Neuroplasticity

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; AMITRIPTYLINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ETOPERIDONE; FLUOXETINE; IPRONIAZID; LUBAZODONE; MAZINDOL; MEMANTINE; MIANSERIN; MIRTAZAPINE; NBI 34041; NEFAZODONE; NIALAMIDE; PAROXETINE; PROCARBAZINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TC 5214; TECIPTILINE; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILAZONE; VILOXAZINE; VORTIOXETINE;

ANXIETY; BRAIN REGION; DENTATE GYRUS; DEPRESSION; DRUG MECHANISM; DRUG STRUCTURE; ELECTROCONVULSIVE THERAPY; HIPPOCAMPUS; HUMAN; MOOD DISORDER; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; OLFACTORY BULB; REVIEW; SUBVENTRICULAR ZONE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; VAGUS NERVE STIMULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AGENTS; HUMANS; MOOD DISORDERS; NICOTINIC ANTAGONISTS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 80052929553     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797200417     Document Type: Review

References (211)

1. Murray, C.J.; Lopez, A.D. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science, 1996, 274(5288), 740-743. (Pubitemid 26398244)
2. The Practice of ECT: Recommendations for Treatment, Training and Privileging. Convuls Ther, 1990, 6(2), 85-120.
3. Nestler, E.J.; Barrot, M.; DiLeone, R.J.; Eisch, A.J.; Gold, S.J.; Monteggia, L.M. Neurobiology of depression. Neuron, 2002, 34(1), 13-25. (Pubitemid 34270695)
4. Lisman, J.E.; Grace, A.A. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron, 2005, 46(5), 703-713. (Pubitemid 40733126)
5. Campbell, S.; Marriott, M.; Nahmias, C.; MacQueen, G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry, 2004, 161 (4), 598-607. (Pubitemid 38445502)
6. Sahay, A.; Hen, R. Adult hippocampal neurogenesis in depression. Nat neurosci., 2007, 10(9), 1110-1115. (Pubitemid 47339960)
7. Czeh, B.; Lucassen, P.J. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? Eur Arch Psychiatry Clin Neurosci., 2007, 257(5), 250-260. (Pubitemid 47301403)
8. Racagni, G.; Popoli, M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci., 2008, 10(4), 385-400.
9. Tanti, A.; Belzung, C. Open questions in current models of antidepressant action. Br J Pharmacol., 159(6), 1187-1200.
10. Eisenhofer, G.; Kopin, I.J.; Goldstein, D.S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev., 2004, 56(3), 331-349. (Pubitemid 39096594)
11. Riederer, P.; Lachenmayer, L.; Laux, G. Clinical applications of MAOinhibitors. Curr Med Chem., 2004, 11(15), 2033-2043.
12. Pitchot, W.; Scantamburlo, G.; Ansseau, M. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine. Psychiatr Danub., 2010, 22 Suppl 1, S106-107.
13. Alvarez, E.; Vinas, F. Mirtazapine in combination. Actas Esp Psiquiatr.,2010, 38(2), 121-128.
14. Silveira, R.O.; Zanatto, V.; Appolinario, J.C.; Kapczinski, F. An open trial of reboxetine in obese patients with binge eating disorder. Eat Weight Disord., 2005, 10(4), e93-96.
15. Montgomery, S.A.; Nil, R.; Durr-Pal, N.; Loft, H.; Boulenger, J.P. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry., 2005, 66(10), 1270-1278. (Pubitemid 41546506)
16. Khan, A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs, 2009, 18(11), 1753-1764.
17. Artigas. In Annual meeting of the European College of Neuropsychopharmacology; September 2009: Instabul, Turkey, 2009.
18. Nakagawa, T.; Ukai, K.; Ohyama, T.; Gomita, Y.; Okamura, H. Effects of sibutramine on the central dopaminergic system in rodents. Neurotox Res., 2001, 3(3), 235-247. (Pubitemid 32962885)
19. McNeely, W.; Goa, K.L. Sibutramine. A review of its contribution to the management of obesity. Drugs, 1998, 56(6), 1093-1124. (Pubitemid 29010230)
20. Hargreaves, R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry. , 2002, 63 Suppl 11, 18-24. (Pubitemid 35435004)
21. Bergstrom, M.; Hargreaves, R.J.; Burns, H.D.; Goldberg, M.R.; Sciberras, D.; Reines, S.A.; Petty, K.J.; Ogren, M.; Antoni, G.; Langstrom, B.; Eskola, O.; Scheinin, M.; Solin, O.; Majumdar, A.K.; Constanzer, M.L.; Battisti,W.P.; Bradstreet, T.E.; Gargano, C.; Hietala, J. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry. , 2004, 55(10), 1007-1012. (Pubitemid 38581916)
22. Bakkar, W.; Ma, C.L.; Pabba, M.; Khacho, P.; Zhang, Y.L.; Muller, E.; Martina, M.; Bergeron, R. Chronically saturating levels of endogenous glycine disrupt glutamatergic neurotransmission and enhance synaptogenesis in the CA1 region of mouse hippocampus. Synapse, 2011, Epub ahead of print
23. Waterhouse, R.N. Imaging the PCP site of the NMDA ion channel. Nucl Med Biol. , 2003, 30(8), 869-878. (Pubitemid 38040996)
24. Stahl, S.M.; Grady, M.M. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry, 2003, 64 Suppl 13, 13-17. (Pubitemid 37267810)
25. Skolnick, P.; Popik, P.; Trullas, R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci., 2009, 30(11), 563-569.
26. Smith, E.J. Amantadine-induced psychosis in a young healthy patient. Am J Psychiatry, 2008, 165(12), 1613.
27. McKeage, K. Memantine: a review of its use in moderate to severe Alzheimer's disease. CNS drugs, 2009, 23(10), 881-897.
28. Arias, H.R.; Rosenberg, A.; Targowska-Duda, K.M.; Feuerbach, D.; Jozwiak, K.; Moaddel, R.; Wainer, I.W. Tricyclic antidepressants and mecamylamine bind to different sites in the human alpha4beta2 nicotinic receptor ion channel. Int J Biochem Cell Biol., 42(6), 1007-1018.
29. Lippiello, P.M.; Beaver, J.S.; Gatto, G.J.; James, J.W.; Jordan, K.G.; Traina, V.M.; Xie, J.; Bencherif, M. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther., 2008, 14(4), 266-277.
30. Dunbar. In Nicotinic Acetylcholine Receptor-Based Therapeutics: Emerging Frontiers in Basic Research and Clinical Science, satellite meeting to the Society for Neuroscience: Chicago, IL, 2009.
31. Holsboer, F.; Ising, M. Central CRH system in depression and anxietyevidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol., 2008, 583(2-3), 350-357.
32. van Bemmel, A.L. The link between sleep and depression: the effects of antidepressants on EEG sleep. J Psychosom Res., 1997, 42(6), 555-564. (Pubitemid 27299950)
33. Wirz-Justice, A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol. , 2006, 21 Suppl 1, S11-15.
34. Olie, J.P.; Kasper, S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol., 2007, 10(5), 661-673. (Pubitemid 47517525)
35. Goodwin, G.M.; Emsley, R.; Rembry, S.; Rouillon, F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebocontrolled trial. J Clin Psychiatry, 2009, 70(8), 1128-1137.
36. Kennedy, S.H.; Rizvi, S.; Fulton, K.; Rasmussen, J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol., 2008, 28(3), 329-333.
37. Haddad, P.M.; Taylor, M.; Niaz, O.S. First-generation antipsychotic longacting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry, 2009, 52, S20-28.
38. Taylor, D. Psychopharmacology and adverse effects of antipsychotic longacting injections: a review. Br J Psychiatry, 2009, 52, S13-19.
39. Kapur, S.; Mamo, D., Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27(7), 1081-1090. (Pubitemid 37464954)
40. Post, R.M.; Calabrese, J.R. Bipolar depression: the role of atypical antipsychotics. Expert Rev Neurother. , 2004, 4(6 Suppl 2), S27-33. (Pubitemid 39482261)
41. Svestka, J. Treatment of bipolar depression. Neuro Endocrinol Lett., 2005, 26 Suppl 1, 27-47.
42. Masan, P.S. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry, 2004, 16(1), 3-13. (Pubitemid 40029199)
43. Montgomery, S.A. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol., 2002, 17 Suppl 4, S9-15; discussion S16-17.
44. Sachs, G.; Sanchez, R.; Marcus, R.; Stock, E.; McQuade, R.; Carson, W.; Abou-Gharbia, N.; Impellizzeri, C.; Kaplita, S.; Rollin, L.; Iwamoto, T. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol., 2006, 20(4), 536-546. (Pubitemid 43875183)
45. Hirose, T.; Uwahodo, Y.; Yamada, S.; Miwa, T.; Kikuchi, T.; Kitagawa, H.; Burris, K.D.; Altar, C.A.; Nabeshima, T. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol., 2004, 18(3), 375-383. (Pubitemid 39382565)
46. Urban, J.D.; Vargas, G.A.; von Zastrow, M.; Mailman, R.B. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology, 2007, 32(1), 67-77. (Pubitemid 44967785)
47. Marder, S.R.; McQuade, R.D.; Stock, E.; Kaplita, S.; Marcus, R.; Safferman, A.Z.; Saha, A.; Ali, M.; Iwamoto, T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res., 2003, 61(2-3), 123-136. (Pubitemid 36513927)
48. Pigott, T.A.; Carson, W.H.; Saha, A.R.; Torbeyns, A.F.; Stock, E.G.; Ingenito, G.G. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry, 2003, 64(9), 1048-1056. (Pubitemid 37158250)
49. Simon, J.S.; Nemeroff, C.B. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005, 66(10), 1216-1220. (Pubitemid 41546499)
50. Papakostas, G.I.; Petersen, T.J.; Kinrys, G.; Burns, A.M.; Worthington, J.J.; Alpert, J.E.; Fava, M.; Nierenberg, A.A. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005, 66(10), 1326-1330. (Pubitemid 41546514)
51. Fulton, B.; Goa, K.L. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs, 1997, 53(2), 281-298. (Pubitemid 27073117)
52. Bymaster, F.P.; Calligaro, D.O.; Falcone, J.F.; Marsh, R.D.; Moore, N.A.; Tye, N.C.; Seeman, P.; Wong, D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 1996, 14(2), 87-96. (Pubitemid 26053226)
53. Harvey, P.D.; Keefe, R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry, 2001, 158(2), 176-184. (Pubitemid 32116511)
54. Purdon, S.E.; Malla, A.; Labelle, A.; Lit, W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci., 2001, 26(2) 137-149. (Pubitemid 32373127)
55. Skarsfeldt, T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology, 1996, 124(1-2), 126-133.
56. Didriksen, M.; Kreilgaard, M.; Arnt, J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol., 2006, 542(1-3), 108-115. (Pubitemid 44066366)
57. Shelton, R.C. Olanzapine/fluoxetine combination for bipolar depression. Expert Rev Neurother., 2006, 6(1), 33-39.
58. Seeman, P. Atypical antipsychotics: mechanism of action. Can J Psychiatry, 2002, 47(1), 27-38. (Pubitemid 34302921)
59. Reynolds, G.P. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol., 2004, 18(3), 340-345. (Pubitemid 39382562)
60. Dando, T.M.; Keating, G.M. Spotlight on quetiapine in acute mania and depression associated with bipolar disorder. CNS drugs, 2006, 20(5), 429-431.
61. Pini, S.; Abelli, M.; Cassano, G.B. The role of quetiapine in the treatment of bipolar disorder. Expert Opin Pharmacother. , 2006, 7(7), 929-940.
62. Moller, H.J. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci., 2005, 255(3), 190-201.
63. Corya, S.A.; Williamson, D.; Sanger, T.M.; Briggs, S.D.; Case, M.; Tollefson, G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression and anxiety, 2006, 23(6), 364-372. (Pubitemid 44619788)
64. Gunasekara, N.S.; Spencer, C.M.; Keating, G.M. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS drugs, 2002, 16(9), 645-652.
65. Bowden, C.L. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry., 2005, 66 Suppl 3, 12-19. (Pubitemid 40461407)
66. Fitzgerald, P.B.; Benitez, J.; de Castella, A.; Daskalakis, Z.J.; Brown, T.L.; Kulkarni, J. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am J Psychiatry, 2006, 163(1), 88-94. (Pubitemid 43050108)
67. UK ECT Review Group.Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet, 2003, 361(9360), 799-808.
68. Walsh, S.P.; Kling, M.A. VNS and depression: current status and future directions. Expert Rev Med Devices, 2004, 1(1), 155-160. (Pubitemid 40220426)
69. Rush, A.J.; Marangell, L.B.; Sackeim, H.A.; George, M.S.; Brannan, S.K.; Davis, S.M.; Howland, R.; Kling, M.A.; Rittberg, B.R.; Burke, W.J.; Rapaport, M.H.; Zajecka, J.; Nierenberg, A.A.; Husain, M.M.; Ginsberg, D.; Cooke, R.G. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry, 2005, 58(5), 347-354. (Pubitemid 41219702)
70. Daskalakis, Z.J.; Levinson, A.J.; Fitzgerald, P.B. Repetitive transcranial magnetic stimulation for major depressive disorder: a review. Can J Psychiatry, 2008, 53(9), 555-566.
71. George, M.S.; Nahas, Z.; Kozel, F.A.; Li, X.; Denslow, S.; Yamanaka, K.; Mishory, A.; Foust, M.J.; Bohning, D.E. Mechanisms and state of the art of transcranial magnetic stimulation. J ECT, 2002, 18(4), 170-181. (Pubitemid 35471056)
72. Fitzgerald, P.B.; Daskalakis, Z.J. The effects of repetitive transcranial magnetic stimulation in the treatment of depression. Expert Rev Med Devices, 8(1), 85-95.
73. Kozel, F.A.; George, M.S. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Psychiatr Pract., 2002, 8(5), 270-275.
74. Loo, C.K.; Sachdev, P.; Mitchell, P.B.; Gandevia, S.C.; Malhi, G.S.; Todd, G.; Taylor, J.L. A study using transcranial magnetic stimulation to investigate motor mechanisms in psychomotor retardation in depression. Int J europsychopharmacol., 2008, 11(7), 935-946.
75. Mayberg, H.S.; Lozano, A.M.; Voon, V.; McNeely, H.E.; Seminowicz, D.; Hamani, C.; Schwalb, J.M.; Kennedy, S.H. Deep brain stimulation for treatment-resistant depression. Neuron, 2005, 45(5), 651-660. (Pubitemid 40320700)
76. Bewernick, B.H.; Hurlemann, R.; Matusch, A.; Kayser, S.; Grubert, C.; Hadrysiewicz, B.; Axmacher, N.; Lemke, M.; Cooper-Mahkorn, D.; Cohen, M.X.; Brockmann, H.; Lenartz, D.; Sturm, V.; Schlaepfer, T.E. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry, 67(2), 110-116.
77. Nestler, E.J.; Carlezon, W.A., Jr. The mesolimbic dopamine reward circuit in depression. Biol psychiatry, 2006, 59(12), 1151-1159. (Pubitemid 44192421)
78. Nemeroff, C.B.; Thase, M.E. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res., 2007, 41(3-4), 351-359. (Pubitemid 44854984)
79. Kinrys, G.; Coleman, E.; Rothstein, E. Natural remedies for anxiety disorders: potential use and clinical applications. Depression and anxiety, 2009, 26(3), 259-265.
80. Pandi-Perumal, S.R.; Srinivasan, V.; Maestroni, G.J.; Cardinali, D.P.; Poeggeler, B.; Hardeland, R. Melatonin: Nature's most versatile biological signal? FEBS J., 2006, 273 (13), 2813-2838.
81. Nowak, J.Z.; Zawilska, J.B. Melatonin and its physiological and therapeutic properties. Pharm World Sci., 1998, 20(1), 18-27. (Pubitemid 28114329)
82. Esposito, E.; Cuzzocrea, S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol., 2010 8(3), 228-242.
83. Ergun, Y.; Ergun, U.G.; Orhan, F.O.; Kucuk, E. Co-administration of a nitric oxide synthase inhibitor and melatonin exerts an additive antidepressant-like effect in the mouse forced swim test. Med Sci Monit., 2006, 12(9), BR307-312.
84. Crupi, R.; Mazzon, E.; Marino, A.; La Spada, G.; Bramanti, P.; Cuzzocrea, S.; Spina, E. Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. J Pineal Res., 2010, 49(2), 123-129.
85. Carvalho, L.A.; Gorenstein, C.; Moreno, R.; Pariante, C.; Markus, R.P. Effect of antidepressants on melatonin metabolite in depressed patients. J Psychopharmacol., 2009, 23(3), 315-321.
86. Zhdanova, I.V.; Giorgetti, M. Melatonin alters behavior and cAMP levels in nucleus accumbens induced by cocaine treatment. Brain Res., 2002, 956(2), 323-331. (Pubitemid 35355724)
87. Ramirez-Rodriguez, G.; Klempin, F.; Babu, H.; Benitez-King, G.; Kempermann, G. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacology, 2009, 34(9), 2180-2191.
88. Caraci, F.; Crupi, R.; Drago, F.; Spina, E. Metabolic Drug Interactions between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract. Curr Drug Metab., 2011, Epub ahead of print.
89. Evans, R.; Moss, S.; Montoya, C.C. Clinical inquiries. Which nutritional therapies are safe and effective for depression? J Fam Pract.,2011, 60(2), 99-100, 100a-100c.
90. Di Paola, R.; Mazzon, E.; Muia, C.; Crisafulli, C.; Genovese, T.; Di Bella, P.; Esposito, E.; Menegazzi, M.; Meli, R.; Suzuki, H.; Cuzzocrea, S. Protective effect of Hypericum perforatum in zymosan-induced multiple organ dysfunction syndrome: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. Nitric Oxide, 2007, 16(1), 118-130. (Pubitemid 44829962)
91. Muller, R.S.; Breitkreutz, J.; Groning, R. Interactions between aqueous Hypericum perforatum extracts and drugs: in vitro studies. Phytother Res., 2004, 18(12), 1019-1023. (Pubitemid 40278929)
92. Hirano, K.; Kato, Y.; Uchida, S.; Sugimoto, Y.; Yamada, J.; Umegaki, K.; Yamada, S. Effects of oral administration of extracts of Hypericum perforatum (St John's wort) on brain serotonin transporter, serotonin uptake and behaviour in mice. J Pharm Pharmacol., 2004, 56(12), 1589-1595. (Pubitemid 39602001)
93. Langosch, J.M.; Zhou, X.Y.; Heinen, M.; Chatterjee, S.S.; Noldner, M.; Walden, J. Effects of Hypericum perforatum L. on evoked potentials in guinea pig hippocampal slices. Pharmacopsychiatry, 2001, 34 Suppl 1, S83-88.
94. Crupi, R.; Mazzon, E.; Marino, A.; La Spada, G.; Bramanti, P.; Battaglia, F.; Cuzzocrea, S.; Spina, E. Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. BMC Complement Altern Med., 2011, 11: 7.
95. Cole, G.M.; Ma, Q.L.; Frautschy, S.A. Dietary fatty acids and the agingbrain. Nutr Rev.,2010, 68 Suppl 2, S102-111.
96. Smith, R.S. The macrophage theory of depression. Med hypotheses, 1991, 35(4), 298-306.
97. Hibbeln, J.R.; Salem, N., Jr. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr., 1995, 62(1), 1-9.
98. Lieb, J.; Karmali, R.; Horrobin, D., Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med., 1983, 10(4), 361-367. (Pubitemid 13162267)
99. Peet, M.; Stokes, C., Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs, 2005, 65(8), 1051-1059. (Pubitemid 40840003)
100. Connor, K.M.; SanGiovanni, J.P.; Lofqvist, C.; Aderman, C.M.; Chen, J.; Higuchi, A.; Hong, S.; Pravda, E.A.; Majchrzak, S.; Carper, D.; Hellstrom, A.; Kang, J.X.; Chew, E.Y.; Salem, N., Jr.; Serhan, C.N.; Smith, L.E. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. , 2007, 13(7), 868-873. (Pubitemid 47038185)
101. Song, C.; Zhao, S., Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: a review of clinical investigations. Expert Opin Investig Drugs, 2007, 16(10), 1627-1638. (Pubitemid 350028412)
102. Beltz, B.S.; Tlusty, M.F.; Benton, J.L.; Sandeman, D.C. Omega-3 fatty acids upregulate adult neurogenesis. Neurosci Lett., 2007, 415(2), 154-158. (Pubitemid 46394591)
103. Song, W.L.; Paschos, G.; Fries, S.; Reilly, M.P.; Yu, Y.; Rokach, J.; Chang, C.T.; Patel, P.; Lawson, J.A.; Fitzgerald, G.A., Novel eicosapentaenoic acidderived F3-isoprostanes as biomarkers of lipid peroxidation. J Biol Chem., 2009, 284(35), 23636-23643.
104. Taepavarapruk, P.; Song, C. Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1beta administrations: effects of omega-3 fatty acid EPA treatment. J Neurochem., 2010, 112(4), 1054-1064.
105. Beck, R.D., Jr.; Wasserfall, C.; Ha, G.K.; Cushman, J.D.; Huang, Z.; Atkinson, M.A.; Petitto, J.M. Changes in hippocampal IL-15, related cytokines, and neurogenesis in IL-2 deficient mice. Brain Res., 2005, 1041(2), 223-230.
106. Ueda, S.; Sakakibara, S.; Yoshimoto, K. Effect of long-lasting serotonin depletion on environmental enrichment-induced neurogenesis in adult rat hippocampus and spatial learning. Neuroscience, 2005, 135(2), 395-402. (Pubitemid 41317378)
107. Kou, W.; Luchtman, D.; Song, C. Eicosapentaenoic acid (EPA) increases cell viability and expression of neurotrophin receptors in retinoic acid and brainderived neurotrophic factor differentiated SH-SY5Y cells. Eur J Nutr., 2008, 47(2), 104-113. (Pubitemid 351667054)
108. Kawakita, E.; Hashimoto, M.; Shido, O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience, 2006, 139(3), 991-997.
109. Heninger, G.R.; Delgado, P.L.; Charney, D.S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry, 1996, 29(1), 2-11. (Pubitemid 26071332)
110. Samuels, B.A.; Hen, R. Neurogenesis and affective disorders. Eur J Neurosci., 2011, 33(6), 1152-1159.
111. Malberg, J.E.; Eisch, A.J.; Nestler, E.J.; Duman, R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci., 2000, 20(24), 9104-9110. (Pubitemid 32042912)
112. Santarelli, L.; Saxe, M.; Gross, C.; Surget, A.; Battaglia, F.; Dulawa, S.; Weisstaub, N.; Lee, J.; Duman, R.; Arancio, O.; Belzung, C.; Hen, R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301(5634), 805-809. (Pubitemid 36962615)
113. Wang, J.W.; David, D.J.; Monckton, J.E.; Battaglia, F.; Hen, R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci., 2008, 28(6), 1374-1384. (Pubitemid 351231535)
114. Banasr, M.; Soumier, A.; Hery, M.; Mocaer, E.; Daszuta, A. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry, 2006, 59(11), 1087-1096. (Pubitemid 43849657)
115. Nibuya, M.; Morinobu, S.; Duman, R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosi., 1995, 15(11), 7539-7547.
116. Coppell, A.L.; Pei, Q.; Zetterstrom, T.S. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology, 2003, 44(7), 903-910. (Pubitemid 36515026)
117. Vinet, J.; Carra, S.; Blom, J.M.; Brunello, N.; Barden, N.; Tascedda, F. Chronic treatment with desipramine and fluoxetine modulate BDNF, CaMKKalpha and CaMKKbeta mRNA levels in the hippocampus of transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuropharmacology, 2004, 47(7), 1062-1069. (Pubitemid 39535845)
118. Russo-Neustadt, A.A.; Alejandre, H.; Garcia, C.; Ivy, A.S.; Chen, M.J. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology, 2004, 29(12), 2189-2199. (Pubitemid 39578909)
119. Deister, C.; Schmidt, C.E. Optimizing neurotrophic factor combinations for neurite outgrowth. J Neural Eng., 2006, 3(2), 172-179. (Pubitemid 43841065)
120. Kandel, E.R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001, 294(5544), 1030-1038. (Pubitemid 33041851)
121. Nibuya, M.; Nestler, E.J.; Duman, R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci., 1996, 16(7), 2365-2372. (Pubitemid 26154346)
122. Frechilla, D.; Otano, A.; Del Rio, J. Effect of chronic antidepressant treatment on transcription factor binding activity in rat hippocampus and frontal cortex. Prog Neuropsychopharmacol Biol Psychiatry, 1998, 22(5), 787-802. (Pubitemid 28396344)
123. West, A.E.; Chen, W.G.; Dalva, M.B.; Dolmetsch, R.E.; Kornhauser, J.M.; Shaywitz, A.J.; Takasu, M.A.; Tao, X.; Greenberg, M.E. Calcium regulation of neuronal gene expression. Proc Natl Acad Sci U S A, 2001, 98(20), 11024-11031. (Pubitemid 32928677)
124. Mayr, B.; Montminy, M. Transcriptional regulation by the phosphorylationdependent factor CREB. Nat Rev Mol Cell Biol., 2001, 2(8), 599-609. (Pubitemid 33674011)
125. Lonze, B.E.; Ginty, D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron, 2002, 35(4), 605-623. (Pubitemid 35229980)
126. Duman, R.S.; Malberg, J.; Nakagawa, S.; D'Sa, C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry, 2000, 48(8), 732-739.
127. Deisseroth, K.; Tsien, R.W. Dynamic multiphosphorylation passwords for activity-dependent gene expression. Neuron, 2002, 34(2), 179-182. (Pubitemid 34442561)
128. Johannessen, M.; Delghandi, M.P.; Moens, U. What turns CREB on? Cell Signal., 2004, 16(11), 1211-1227. (Pubitemid 39165450)
129. Choi, J.S.; Kim, J.A.; Joo, C.K. Activation of MAPK and CREB by GM1 induces survival of RGCs in the retina with axotomized nerve. Invest Ophthalmol Vis Sci. , 2003, 44(4), 1747-1752.
130. Arthur, J.S.; Fong, A.L.; Dwyer, J.M.; Davare, M.; Reese, E.; Obrietan, K.; Impey, S. Mitogen- and stress-activated protein kinase 1 mediates cAMP response element-binding protein phosphorylation and activation by neurotrophins. J Neurosci., 2004, 24(18), 4324-4332. (Pubitemid 38608143)
131. Duman, R.S.; Monteggia, L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry, 2006, 59(12), 1116-1127.
132. Martinowich, K.; Manji, H.; Lu, B. New insights into BDNF function in depression and anxiety. Nat Neurosci., 2007, 10(9), 1089-1093. (Pubitemid 47339961)
133. Groves, J.O. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry, 2007, 12(12), 1079-1088. (Pubitemid 350191365)
134. Wang, J.W.; Dranovsky, A.; Hen, R. The when and where of BDNF and the antidepressant response. Biol Psychiatry, 2008, 63(7), 640-641. (Pubitemid 351329282)
135. Koponen, E.; Rantamaki, T.; Voikar, V.; Saarelainen, T.; MacDonald, E.; Castren, E. Enhanced BDNF signaling is associated with an antidepressantlike behavioral response and changes in brain monoamines. Cell Mol Neurobiol., 2005, 25(6), 973-980. (Pubitemid 43154821)
136. Utge, S.; Soronen, P.; Partonen, T.; Loukola, A.; Kronholm, E.; Pirkola, S.; Nyman, E.; Porkka-Heiskanen, T.; Paunio, T. A population-based association study of candidate genes for depression and sleep disturbance. Am J Med Genet B Neuropsychiatr Genet., 153B(2), 468-476.
137. Gatt, J.M.; Nemeroff, C.B.; Dobson-Stone, C.; Paul, R.H.; Bryant, R.A.; Schofield, P.R.; Gordon, E.; Kemp, A.H.; Williams, L.M. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry, 2009, 14(7), 681-695.
138. Golimbet, V.; Alfimova, M.; Korovaitseva, G.; Abramova, L.I.; Kaled, V.G. Emotional distress in parents of psychotic patients is modified by serotonin transporter gene (5-HTTLPR)-brain-derived neurotrophic factor gene interactions. Span J Psychol., 2009, 12(2), 696-706.
139. Jiang, X.; Zhou, J.; Mash, D.C.; Marini, A.M.; Lipsky, R.H. Human BDNF isoforms are differentially expressed in cocaine addicts and are sorted to the regulated secretory pathway independent of the Met66 substitution. Neuromolecular Med., 2009, 11(1), 1-12.
140. Huang, R.; Huang, J.; Cathcart, H.; Smith, S.; Poduslo, S.E. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease. J Med Genet., 2007, 44(2), e66.
141. Kunugi, H.; Hori, H.; Adachi, N.; Numakawa, T. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin Neurosci.,2010, 64(5), 447-459.
142. De Foubert, G.; Carney, S.L.; Robinson, C.S.; Destexhe, E.J.; Tomlinson, R.; Hicks, C.A.; Murray, T.K.; Gaillard, J.P.; Deville, C.; Xhenseval, V.; Thomas, C.E.; O'Neill, M.J.; Zetterstrom, T.S. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience, 2004, 128(3), 597-604. (Pubitemid 39277429)
143. Fazeli, M.S.; Corbet, J.; Dunn, M.J.; Dolphin, A.C.; Bliss, T.V. Changes in protein synthesis accompanying long-term potentiation in the dentate gyrus in vivo. J Neurosci., 1993, 13(4), 1346-1353. (Pubitemid 23095381)
144. Citri, A.; Malenka, R.C. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology, 2008, 33(1), 18-41. (Pubitemid 350191314)
145. Isaac, J.T.; Oliet, S.H.; Hjelmstad, G.O.; Nicoll, R.A.; Malenka, R.C. Expression mechanisms of long-term potentiation in the hippocampus. J Physiol Paris, 1996, 90(5-6), 299-303. (Pubitemid 27113364)
146. Kandler, K.; Katz, L.C.; Kauer, J.A. Focal photolysis of caged glutamate produces long-term depression of hippocampal glutamate receptors. Nat Neurosci., 1998, 1(2), 119-123.
147. Carroll, R.C.; Lissin, D.V.; von Zastrow, M.; Nicoll, R.A.; Malenka, R.C. Rapid redistribution of glutamate receptors contributes to long-term depression in hippocampal cultures. Nat Neurosci., 1999, 2(5), 454-460. (Pubitemid 30491256)
148. Benke, T.A.; Luthi, A.; Isaac, J.T.; Collingridge, G.L. Modulation of AMPA receptor unitary conductance by synaptic activity. Nature, 1998, 393(6687), 793-797. (Pubitemid 28299491)
149. Nayak, A.; Zastrow, D.J.; Lickteig, R.; Zahniser, N.R.; Browning, M.D. Maintenance of late-phase LTP is accompanied by PKA-dependent increase in AMPA receptor synthesis. Nature, 1998, 394(6694), 680-683. (Pubitemid 28389794)
150. Engert, F.; Bonhoeffer, T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature, 1999, 399(6731), 66-70.
151. Barria, A.; Muller, D.; Derkach, V.; Griffith, L.C.; Soderling, T.R. Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. Science, 1997, 276(5321), 2042-2045. (Pubitemid 27443609)
152. Lee, H.K.; Barbarosie, M.; Kameyama, K.; Bear, M.F.; Huganir, R.L. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature, 2000, 405(6789), 955-959. (Pubitemid 30435052)
153. Pittenger, C.; Sanacora, G.; Krystal, J.H. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets, 2007, 6(2), 101-115. (Pubitemid 46681771)
154. Holderbach, R.; Clark, K.; Moreau, J.L.; Bischofberger, J.; Normann, C. Enhanced long-term synaptic depression in an animal model of depression. Biol Psychiatry, 2007, 62 (1), 92-100. (Pubitemid 46898221)
155. Hashimoto, K.; Sawa, A.; Iyo, M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry, 2007, 62(11), 1310-1316. (Pubitemid 350060893)
156. Sanacora, G.; Gueorguieva, R.; Epperson, C.N.; Wu, Y.T.; Appel, M.; Rothman, D.L.; Krystal, J.H.; Mason, G.F. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry, 2004, 61(7), 705-713. (Pubitemid 38890805)
157. Watanabe, Y.; Gould, E.; McEwen, B.S. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res., 1992, 588(2), 341-345.
158. Kole, M.H.; Swan, L.; Fuchs, E. The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. Eur J Neurosci., 2002, 16(5), 807-816. (Pubitemid 35463572)
159. Skolnick, P. Antidepressants for the new millennium. Eur J Pharmacol., 1999, 375(1-3), 31-40. (Pubitemid 29317590)
160. Rocher, C.; Spedding, M.; Munoz, C.; Jay, T.M. Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. Cereb Cortex, 2004, 14(2), 224-229. (Pubitemid 38141538)
161. Bonanno, G.; Giambelli, R.; Raiteri, L.; Tiraboschi, E.; Zappettini, S.; Musazzi, L.; Raiteri, M.; Racagni, G.; Popoli, M. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci., 2005, 25(13), 3270-3279. (Pubitemid 40471335)
162. Von Frijtag, J.C.; Kamal, A.; Reijmers, L.G.; Schrama, L.H.; van den Bos, R.; Spruijt, B.M. Chronic imipramine treatment partially reverses the longterm changes of hippocampal synaptic plasticity in socially stressed rats. Neurosci Lett, 2001, 309(3), 153-156. (Pubitemid 32763162)
163. Zarate, C.A., Jr.; Du, J.; Quiroz, J.; Gray, N.A.; Denicoff, K.D.; Singh, J.; Charney, D.S.; Manji, H.K. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Annals of the New York Academy of Sciences, 2003, 1003, 273-291. (Pubitemid 38083062)
164. Paul, I.A.; Skolnick, P., Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci., 2003, 1003, 250-272. (Pubitemid 38083061)
165. Pittaluga, A.; Raiteri, L.; Longordo, F.; Luccini, E.; Barbiero, V.S.; Racagni, G.; Popoli, M.; Raiteri, M. Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology, 2007, 53(1), 27-36. (Pubitemid 47125945)
166. Ryan, B.; Musazzi, L.; Mallei, A.; Tardito, D.; Gruber, S.H.; El Khoury, A.; Anwyl, R.; Racagni, G.; Mathe, A.A.; Rowan, M.J.; Popoli, M. Remodelling by early-life stress of NMDA receptor-dependent synaptic plasticity in a gene-environment rat model of depression. Int J Neuropsychopharmacol., 2009, 12(4), 553-559.
167. Goldman, S.A.; Nottebohm, F., Neuronal production, migration, and differentiation in a vocal control nucleus of the adult female canary brain. Proc Natl Acad Sci U S A, 1983, 80(8), 2390-2394. (Pubitemid 13097195)
168. Nottebohm, F. Neuronal replacement in adulthood. Annals of the New York Academy of Sciences, 1985, 457, 143-161. (Pubitemid 16129908)
169. Luskin, M.B. Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone. Neuron, 1993, 11(1), 173-189. (Pubitemid 23222544)
170. Carlen, M.; Cassidy, R.M.; Brismar, H.; Smith, G.A.; Enquist, L.W.; Frisen, J. Functional integration of adult-born neurons. Curr Biol., 2002, 12(7), 606-608. (Pubitemid 34271377)
171. Eriksson, P.S.; Perfilieva, E.; Bjork-Eriksson, T.; Alborn, A.M.; Nordborg, C.; Peterson, D.A.; Gage, F.H. Neurogenesis in the adult human hippocampus. Nat Med., 1998, 4(11), 1313-1317. (Pubitemid 28512114)
172. Boldrini, M.; Underwood, M.D.; Hen, R.; Rosoklija, G.B.; Dwork, A.J.; John Mann, J.; Arango, V. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology, 2009, 34(11), 2376-2389.
173. Halbach, O.v.B.u. Immunohistological markers for staging neurogenesis in adult hippocampus. Cell Tissue Res, 2007, (329), 409-420.
174. Fukuda, S.; Kato, F.; Tozuka, Y.; Yamaguchi, M.; Miyamoto, Y.; Hisatsune, T. Two distinct subpopulations of nestin-positive cells in adult mouse dentate gyrus. J Neurosci., 2003, 23(28), 9357-9366. (Pubitemid 37323035)
175. Seri, B.; Garcia-Verdugo, J.M.; McEwen, B.S.; Alvarez-Buylla, A. Astrocytes give rise to new neurons in the adult mammalian hippocampus. J Neurosci., 2001, 21(18), 7153-7160. (Pubitemid 32846963)
176. Eckenhoff, M.F.; Rakic, P. Radial organization of the hippocampal dentate gyrus: a Golgi, ultrastructural, and immunocytochemical analysis in the developing rhesus monkey. J Comp Neurol., 1984, 223(1), 1-21. (Pubitemid 14186769)
177. Hartfuss, E.; Galli, R.; Heins, N.; Gotz, M. Characterization of CNS precursor subtypes and radial glia. Dev Biol. , 2001, 229(1), 15-30. (Pubitemid 32061711)
178. Bull, N.D.; Bartlett, P.F. The adult mouse hippocampal progenitor is neurogenic but not a stem cell. J Neurosci., 2005, 25(47), 10815-10821. (Pubitemid 41692611)
179. Kempermann, G.; Kronenberg, G. Depressed new neurons-adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry, 2003, 54(5), 499-503. (Pubitemid 37289436)
180. Ming, G.L.; Song, H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci., 2005, 28, 223-250. (Pubitemid 41098905)
181. Brandt, M.D.; Jessberger, S.; Steiner, B.; Kronenberg, G.; Reuter, K.; Bick-Sander, A.; von der Behrens, W.; Kempermann, G. Transient calretinin expression defines early postmitotic step of neuronal differentiation in adult hippocampal neurogenesis of mice. Mol Cell Neurosci., 2003, 24(3), 603-613. (Pubitemid 37506005)
182. Kempermann, G.; Jessberger, S.; Steiner, B.; Kronenberg, G. Milestones of neuronal development in the adult hippocampus. Trends Neurosci., 2004, 27(8), 447-452. (Pubitemid 38951037)
183. Baimbridge, K.G.; Celio, M.R.; Rogers, J.H. Calcium-binding proteins in the nervous system. Trends Neurosci., 1992, 15(8), 303-308.
184. van Praag, H.; Schinder, A.F.; Christie, B.R.; Toni, N.; Palmer, T.D.; Gage, F.H. Functional neurogenesis in the adult hippocampus. Nature, 2002, 415(6875), 1030-1034. (Pubitemid 34193451)
185. Kuhn, H.G.; Dickinson-Anson, H.; Gage, F.H. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci, 1996, 16(6), 2027-2033. (Pubitemid 26144015)
186. Song, H.J.; Stevens, C.F.; Gage, F.H. Neural stem cells from adult hippocampus develop essential properties of functional CNS neurons. Nat Neurosci., 2002, 5(5), 438-445. (Pubitemid 34454249)
187. Zhao, C.; Deng, W.; Gage, F.H. Mechanisms and functional implications of adult neurogenesis. Cell, 2008, 132(4), 645-660. (Pubitemid 351253687)
188. Eisch, A.J.; Cameron, H.A.; Encinas, J.M.; Meltzer, L.A.; Ming, G.L.; Overstreet-Wadiche, L.S. Adult neurogenesis, mental health, and mental illness: hope or hype? J Neurosci., 2008, 28 (46), 11785-11791.
189. Ulrich-Lai, Y.M.; Herman, J.P. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci., 2009, 10(6), 397-409.
190. Czeh, B.; Welt, T.; Fischer, A.K.; Erhardt, A.; Schmitt, W.; Muller, M.B.; Toschi, N.; Fuchs, E.; Keck, M.E. Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biol Psychiatry, 2002, 52(11), 1057-1065. (Pubitemid 35379963)
191. Murray, K.D.; Rubin, C.M.; Jones, E.G.; Chalupa, L.M. Molecular correlates of laminar differences in the macaque dorsal lateral geniculate nucleus. J Neurosci., 2008, 28(46), 12010-12022.
192. David, D.J.; Samuels, B.A.; Rainer, Q.; Wang, J.W.; Marsteller, D.; Mendez, I.; Drew, M.; Craig, D.A.; Guiard, B.P.; Guilloux, J.P.; Artymyshyn, R.P.; Gardier, A.M.; Gerald, C.; Antonijevic, I.A.; Leonardo, E.D.; Hen, R. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron, 2009, 62(4), 479-493.
193. Chen, H.; Pandey, G.N.; Dwivedi, Y. Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport, 2006, 17(9), 863-867. (Pubitemid 43869948)
194. David, D.J.; Wang, J.; Samuels, B.A.; Rainer, Q.; David, I.; Gardier, A.M.; Hen, R. Implications of the functional integration of adult-born hippocampal neurons in anxiety-depression disorders. Neuroscientist, 16(5), 578-591.
195. Kempermann, G.; Gage, F.H. Neurogenesis in the adult hippocampus. Novartis Foundation symposium, 2000, 231, 220-235; discussion 235-241, 302-226.
196. Suh, H.; Consiglio, A.; Ray, J.; Sawai, T.; D'Amour, K.A.; Gage, F.H. In vivo fate analysis reveals the multipotent and self-renewal capacities of Sox2+ neural stem cells in the adult hippocampus. Cell Stem Cell, 2007, 1(5), 515-528. (Pubitemid 350056408)
197. Steiner, B.; Klempin, F.; Wang, L.; Kott, M.; Kettenmann, H.; Kempermann, G. Type-2 cells as link between glial and neuronal lineage in adult hippocampal neurogenesis. Glia, 2006, 54(8), 805-814. (Pubitemid 44671986)
198. Meyer, J.H.; Kapur, S.; Eisfeld, B.; Brown, G.M.; Houle, S.; DaSilva, J.; Wilson, A.A.; Rafi-Tari, S.; Mayberg, H.S.; Kennedy, S.H. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry, 2001, 158(1), 78-85. (Pubitemid 32047250)
199. Seminowicz, D.A.; Mayberg, H.S.; McIntosh, A.R.; Goldapple, K.; Kennedy, S.; Segal, Z.; Rafi-Tari, S. Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage, 2004, 22(1), 409-418. (Pubitemid 38515850)
200. Blier, P.; de Montigny, C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry, 1998, 44(5), 313-323. (Pubitemid 28432642)
201. Slattery, D.A.; Hudson, A.L.; Nutt, D.J. Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol., 2004, 18(1), 1-21. (Pubitemid 38200913)
202. Richardson-Jones, J.W.; Craige, C.P.; Guiard, B.P.; Stephen, A.; Metzger, K.L.; Kung, H.F.; Gardier, A.M.; Dranovsky, A.; David, D.J.; Beck, S.G.; Hen, R.; Leonardo, E.D. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron, 2010, 65(1), 40-52.
203. Singh, G.; Binstadt, B.A.; Black, D.F.; Corr, A.P.; Rummans, T.A. Electroconvulsive therapy and Friedreich's ataxia. J ECT, 2001, 17(1), 53-54. (Pubitemid 32246867)
204. van Praag, H.M. Can stress cause depression? World J Biol Psychiatry, 2005, 6 Suppl 2, 5-22.
205. Schloesser, R.J.; Lehmann, M.; Martinowich, K.; Manji, H.K.; Herkenham, M. Environmental enrichment requires adult neurogenesis to facilitate the recovery from psychosocial stress. Mol Psychiatry, 15(12), 1152-1163.
206. Li, Y.; Luikart, B.W.; Birnbaum, S.; Chen, J.; Kwon, C.H.; Kernie, S.G.; Bassel-Duby, R.; Parada, L.F. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron, 2008, 59(3), 399-412.
207. Warner-Schmidt, J.L.; Duman, R.S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A, 2007, 104(11), 4647-4652. (Pubitemid 47186279)
208. Palmer, T.D.; Willhoite, A.R.; Gage, F.H. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol. , 2000, 425(4), 479-494.
209. Meshi, D.; Drew, M.R.; Saxe, M.; Ansorge, M.S.; David, D.; Santarelli, L.; Malapani, C.; Moore, H.; Hen, R. Hippocampal neurogenesis is not required for behavioral effects of environmental enrichment. Nat Neurosci., 2006, 9(6), 729-731.
210. Saxe, M.D.; Battaglia, F.; Wang, J.W.; Malleret, G.; David, D.J.; Monckton, J.E.; Garcia, A.D.; Sofroniew, M.V.; Kandel, E.R.; Santarelli, L.; Hen, R.; Drew, M.R. Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc Natl Acad Sci U S A., 2006, 103(46), 17501-17506. (Pubitemid 44788998)
211. Chrousos, G.P. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann N Y Acad Sci., 1998, 851, 311-335.